{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 110 of 129', 'Not related', 'Does not follow a reasonable temporal sequence from administration of the', 'IMP.', \"Is better explained by other factors like the subject's clinical state,\", 'environmental or toxic factors or other therapies administered to the subject.', 'Does not reappear or worsen upon re-challenge.', 'Does not follow a known pattern of response to the IMP.', 'Similarly, the causal relationship to the use of NIMP (TCS) should also be evaluated using the', 'same definitions as for the IMP (i.e. probably, possibly, or not related to NIMP).', 'Outcome', 'The outcome of the event should be classified and handled as follows:', 'Recovered/', 'The event has stopped. The stop date of the event must be recorded.', 'resolved', 'Recovering/', 'The subject is clearly recovering from an event. The event is not yet', 'resolving', 'completely resolved.', 'Not', 'Event is still ongoing.', 'recovered/', 'not resolved', 'Recovered/re', 'The event has reached a state where no further changes are expected and the', 'solved with', 'residual symptoms are assumed to persist. An example is hemiparesis after', 'sequelae', 'stroke.', 'The stop date of the event must be recorded. In case of a SAE, the sequelae', 'should be specified.', 'Fatal', 'The subject has died as a consequence of the event. Date of death is recorded', 'as stop date for the AE.', 'Unknown', 'Unknown to investigator, e.g. subject lost to follow-up.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 111 of 129', 'Appendix 3: Trial governance considerations', 'Appendix 3A: Regulatory and ethical considerations', 'This trial will be conducted in accordance with the protocol and with the following:', 'Consensus ethical principles derived from international guidelines including', 'the current version of the Declaration of Helsinki and Council for International', 'Organizations of Medical Sciences (CIOMS) International Ethical Guidelines.', 'Current version of applicable ICH GCP Guidelines.', 'Applicable laws and regulations.', 'The appropriate regulatory authority(ies) must be notified of/approve the clinical trial as', 'required.', 'The protocol, protocol amendments, subject information leaflet including the informed', \"consent form (ICF), Investigator's Brochure, and other relevant documents (for example\", 'advertisements) must be submitted to an IRB/IEC by the investigator (in collaboration with', 'LEO, if applicable) and reviewed and approved by the IRB/IEC prior to enrolment of', 'subjects.', 'Any amendments to the protocol must be approved by/receive favourable opinion from', 'relevant regulatory authorities and IRBs/IECs as required prior to the implementation.', 'The investigator will be responsible for the following:', 'Providing written summaries of the status of the trial to the IRB/IEC annually', 'or more frequently in accordance with the requirements, policies, and', 'procedures established by the IRB/IEC.', 'Notifying the local IRB/IEC of SAEs or other significant safety findings as', 'required by IRB/IEC procedures.', 'Providing oversight of the conduct of the trial at the trial site and adherence to', 'applicable national and international legislation.', 'Appendix 3B: Informed consent process', 'Subjects shall receive written and verbal information concerning the clinical trial. This', 'information will emphasise that participation in the clinical trial is voluntary and that the', 'subject may withdraw from the clinical trial at any time and for any reason. All subjects will', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 112 of 129', 'be given an opportunity to ask questions and will be given sufficient time to consider before', 'consenting.', \"The subject's signed and dated informed consent to participate in the clinical trial must be\", 'obtained prior to any clinical trial related procedure being carried out in accordance with ICH', 'GCP (4.8) and all applicable laws and regulations. The authorised person obtaining the', 'informed consent must also sign the ICF.', 'Subjects must be re-consented to the most current version of the ICF(s) during their', 'participation in the trial, if applicable.', \"A copy of the ICF(s) must be provided to the subject or the subject's legally authorised\", 'representative.', 'Subject card', 'At screening, subjects will be provided with a card stating that they are participating in a', 'clinical trial and which contains contact address(es) and telephone number(s) of relevant trial', 'site staff including the number for the investigator in case of emergency situations. The', 'subject card also includes a local telephone number for the emergency unblinding CRO to be', 'used if the investigator or delegated site staff cannot be reached or if unblinding in the IWRS', 'cannot be performed.', 'Appendix 3C: Subject and data confidentiality', 'This clinical trial protocol as well as all other information, data and results relating to this', 'clinical trial and/or to the IMP is confidential information of LEO and shall not be used by the', 'investigator for purposes other than this clinical trial.', 'The investigator agrees that LEO may use any and all information, data and results from this', 'clinical trial in connection with the development of the IMPs and, therefore, may disclose', 'and/or transfer information, data and/or results to other investigators, regulatory authorities', 'and/or commercial partners.', \"Subjects will be assigned a unique identifier (subject ID) by LEO. Any subject's records or\", 'datasets that are transferred to LEO will contain the identifier only; subject names or any', 'information which would make the subject identifiable will not be transferred.', 'Subjects must be informed that their personal trial-related data will be used by LEO in', 'accordance with local data protection law.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}